Could Remdesivir be used in the Presence of Elevated Liver Enzymes Secondary to COVID-19 Infection in Children? A Case Report.

Shirin Sayyahfar, Sanaz Khajouii, Elham Zarei, Motahareh Tahami

Abstract readCase Reports

In one paragraph

Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shirin SayyahfarResearch Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Sanaz KhajouiiDepartment of Pediatrics, Ali Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Elham ZareiDepartment of Radiology, Ali Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Motahareh TahamiDepartment of Pediatrics, Ali Asghar Children's Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormal liver biochemistry values are not unusual in patients with COVID-19 infection. Remdesivir is one of the drugs that is currently used for the treatment of COVID-19 infection, but one of the side effects of this drug is hepatotoxicity. According to the local guidelines of the Iranian Ministry of Health, remdesivir should be monitored serially before, during, and at the end of treatment, and withheld if liver function tests (LFTs) rise more than 5 times the upper limit of normal. Herein, we report a pediatric case of severe acute respiratory syndrome (SARS) coronavirus (CoV)-2(SARS-CoV-2) pneumonia and elevated liver enzymes who was treated with remdesivir despite the first LFTs of more than five times the upper limit of normal. The LFTs improved during treatment and reached near-normal values at the time of hospital discharge. Indications of remdesivir usage in the setting of elevated liver enzymes due to SARS-CoV-2 infection remain to be defined.

Indexed as

COVID-19HepatitisLiver enzymePandemicsRemdesivir

Identifiers

PMID42757043

PMCPMC13585210

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.